New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:37 EDTENTAEnanta Pharmaceuticals reports Q1 EPS (30c), consensus (15c)
Reports Q1 revenue $893K, consensus $1.41M. The company said, "The changes in revenue for the three-month periods are primarily related to the timing and amount of milestone and other payments from collaborations, which have varied significantly from period to period and are expected to continue to do so."
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
18:49 EDTENTAEnanta will not exercise co-development option for ABT-493
Enanta Pharmaceuticals (ENTA) announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus, or HCV, being developed in Enanta’s collaboration with AbbVie (ABBV). Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens. Enanta also announced that it has reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.
October 15, 2014
09:57 EDTENTALeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
10:44 EDTENTAEnanta strength attributed to a positive mention by Navellier
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use